These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 22902995

  • 21. Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer.
    Seo JH, Jung KH, Son MK, Yan HH, Ryu YL, Kim J, Lee JK, Hong S, Hong SS.
    Cancer Lett; 2013 Sep 28; 338(2):271-81. PubMed ID: 23587795
    [Abstract] [Full Text] [Related]

  • 22. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
    Shi L, Yang F, Luo F, Liu Y, Zhang F, Zou M, Liu Q.
    Tumour Biol; 2016 Sep 28; 37(9):12791-12803. PubMed ID: 27449032
    [Abstract] [Full Text] [Related]

  • 23. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 24. GYY4137, a hydrogen sulfide (H₂S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway.
    Lu S, Gao Y, Huang X, Wang X.
    Int J Oncol; 2014 Apr 15; 44(4):1259-67. PubMed ID: 24535538
    [Abstract] [Full Text] [Related]

  • 25. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC.
    J Hepatol; 2010 Jan 15; 52(1):79-87. PubMed ID: 19910069
    [Abstract] [Full Text] [Related]

  • 26. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X, Wang X, Ye H, Peng A, Chen L.
    Cancer Chemother Pharmacol; 2012 Sep 15; 70(3):425-37. PubMed ID: 22814678
    [Abstract] [Full Text] [Related]

  • 27. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities.
    Hong SW, Jung KH, Lee HS, Son MK, Yan HH, Kang NS, Lee J, Hong SS.
    Carcinogenesis; 2013 Sep 15; 34(9):2156-69. PubMed ID: 23671132
    [Abstract] [Full Text] [Related]

  • 28. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
    Huynh H, Ong R, Soo KC.
    Angiogenesis; 2012 Mar 15; 15(1):59-70. PubMed ID: 22187171
    [Abstract] [Full Text] [Related]

  • 29. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM.
    Anticancer Res; 2012 Jul 15; 32(7):2531-6. PubMed ID: 22753710
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
    Li WC, Ye SL, Sun RX, Liu YK, Tang ZY, Kim Y, Karras JG, Zhang H.
    Clin Cancer Res; 2006 Dec 01; 12(23):7140-8. PubMed ID: 17145839
    [Abstract] [Full Text] [Related]

  • 31. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
    Yun SM, Jung KH, Lee H, Son MK, Seo JH, Yan HH, Park BH, Hong S, Hong SS.
    Cancer Lett; 2013 May 01; 331(2):250-61. PubMed ID: 23340175
    [Abstract] [Full Text] [Related]

  • 32. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.
    Biochem Pharmacol; 2012 May 01; 83(9):1146-58. PubMed ID: 22285225
    [Abstract] [Full Text] [Related]

  • 33. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY.
    Clin Cancer Res; 2008 Aug 15; 14(16):5124-30. PubMed ID: 18698030
    [Abstract] [Full Text] [Related]

  • 34. Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells.
    Ryu YL, Jung KH, Son MK, Yan HH, Kim SJ, Shin S, Hong S, Hong SS.
    Cancer Lett; 2014 Oct 10; 353(1):68-77. PubMed ID: 25016056
    [Abstract] [Full Text] [Related]

  • 35. An ethyl acetate fraction of Artemisia capillaris (ACE-63) induced apoptosis and anti-angiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma.
    Jung KH, Rumman M, Yan H, Cheon MJ, Choi JG, Jin X, Park S, Oh MS, Hong SS.
    Phytother Res; 2018 Oct 10; 32(10):2034-2046. PubMed ID: 29972254
    [Abstract] [Full Text] [Related]

  • 36. Small molecular anticancer agent SKLB703 induces apoptosis in human hepatocellular carcinoma cells via the mitochondrial apoptotic pathway invitro and inhibits tumor growth invivo.
    Xu YZ, Zheng RL, Zhou Y, Peng F, Lin HJ, Bu Q, Mao YQ, Yu LT, Yang L, Yang SY, Zhao YL.
    Cancer Lett; 2011 Dec 26; 313(1):44-53. PubMed ID: 21944661
    [Abstract] [Full Text] [Related]

  • 37. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts.
    Jia WD, Xu GL, Xu RN, Sun HC, Wang L, Yu JH, Wang J, Li JS, Zhai ZM, Xue Q.
    J Cancer Res Clin Oncol; 2003 Jun 26; 129(6):327-34. PubMed ID: 12811549
    [Abstract] [Full Text] [Related]

  • 38. A novel imidazopyridine analogue as a phosphatidylinositol 3-kinase inhibitor against human breast cancer.
    Lee H, Li GY, Jeong Y, Jung KH, Lee JH, Ham K, Hong S, Hong SS.
    Cancer Lett; 2012 May 01; 318(1):68-75. PubMed ID: 22155744
    [Abstract] [Full Text] [Related]

  • 39. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
    Kim SJ, Jung KH, Son MK, Park JH, Yan HH, Fang Z, Kang YW, Han B, Lim JH, Hong SS.
    Cancer Lett; 2017 Sep 10; 403():339-353. PubMed ID: 28688971
    [Abstract] [Full Text] [Related]

  • 40. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.
    Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, Djonov V, Stoupis C, Dufour JF.
    J Hepatol; 2007 May 10; 46(5):840-8. PubMed ID: 17321636
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.